Evolus Announces Study In "JAMA Dermatology", Finds Jeuveau Outperforms Botox, Dysport, and Xeomin In Onset, Peak Effect, And Duration

• First head-to-head study of four United States (U.S.) Food & Drug Administration (FDA) approved neurotoxins: Jeuveau®, Botox®, Dysport®, and Xeomin®
• The study published in JAMA Dermatology supports fast onset, strong peak effect, and long duration for Jeuveau®

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the publication of a landmark independent study in JAMA Dermatology directly comparing four leading botulinum toxin type A products for the treatment of glabellar lines: Jeuveau® (prabotulinumtoxinA-xvfs), Botox® (onabotulinumtoxinA), Dysport® (abobotulinumtoxinA), and Xeomin® (incobotulinumtoxinA).

In the double-blind, randomized study conducted at the University of Pennsylvania, 143 female participants aged 30 to 65 were treated with FDA-approved doses of either Jeuveau®, Botox®, Dysport®, or Xeomin®. Using advanced 3-dimensional photogrammetry, researchers quantified dynamic facial strain to objectively measure efficacy at days 3, 30, 90, and 180.

Key published findings include:

• Fast Onset of Action: Jeuveau® and Dysport® demonstrated significantly faster visible effects at Day 3 compared to Botox® and Xeomin®.
• Strong Peak Effect: Jeuveau® achieved the highest peak effect at Day 30, with a median strain reduction of 93%, highlighting its robust performance profile.
• Long Duration of Effect: Jeuveau® had significant duration at Day 180 compared with baseline and was significantly more effective than Botox® at this time point.